Tag: Algernon Pharmaceuticals - Psychedelic Alpha

Read more about the article Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Post published:September 6, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Post published:August 8, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Post published:July 15, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Post published:June 27, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Post published:June 6, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Post published:June 5, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Post published:May 31, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Closing of Rights Offering

Algernon Pharmaceuticals Announces Closing of Rights Offering

Post published:May 6, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Post published:April 20, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Post published:April 17, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.